Nanjing Santong Pharmaceutical Technology

Nanjing Santong Pharmaceutical Technology is a clinical-stage biotechnology company based in China that focuses on the development of innovative metabolic and endocrine therapies. The company specializes in the design and optimization of multi-target peptide drugs, particularly those targeting the GLP-1, GIP, and Glucagon receptors for the treatment of obesity and type 2 diabetes. Their lead programs aim to provide improved efficacy and safety profiles compared to existing incretin-based therapies. Santong Pharmaceutical leverages its expertise in peptide chemistry to advance a pipeline of candidates through clinical development in the Chinese market.